Geron Corp
GERNGeron Corporation is a biotechnology company focusing on developing innovative therapies for cancer and regenerative medicine. It is known for its work in telomerase inhibition, aiming to treat cancer by targeting the enzyme crucial for cancer cell immortality, and exploring strategies for tissue repair and regenerative therapies.
Company News
Geron Corporation plans to reduce workforce by one-third and streamline operations to improve financial discipline, focusing on RYTELO commercial growth and clinical development while reducing 2026 operating expenses.
Multiple biotech companies are advancing innovative immunotherapy and targeted treatments for blood cancers, with significant clinical trial progress and FDA approvals in acute myeloid leukemia (AML) and related hematologic conditions.
Law firm investigating potential claims against Geron Corporation regarding alleged misleading statements about drug Rytelo's launch and growth potential during February 2024-2025 period.
Biotechnology company Cassava Sciences announced the appointment of Dawn C. Bir to its Board of Directors, bringing extensive biopharmaceutical executive experience to support the company's clinical development of simufilam for TSC-related epilepsy.
Geron Corporation has appointed four new executives, including Ahmed ElNawawi as Chief Commercial Officer, to lead commercial strategy and drive growth for its blood cancer treatment RYTELO®.
